Market Cap
$26.1B
WST
WEST PHARMACEUTICAL SERVICES INC
$365.03 ▲ +0.01%
Prev close $365.01Market cap$26.1B
ConsensusStrong Buy
12-mo target$407.56 (+11.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)34 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on WST right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$18.4B
Inst. Activity
34 buys / 16 sells
Insider Activity
$0.00 buy / $6.6M sell
Insider Net $
-$6.6M
SEC Reports
12
Price chart 30d +6.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Insider
HAUGEN JANET BRUTSCHEA was granted 44 shares
Director @ $370.76 ($16.3K)
Sep 15, 2026 Insider
Favorite Annette F acquired via exercise 2,524 shares
Sr. VP & Chief HR Officer @ $89.64 ($226.3K)
Sep 15, 2026 Insider
Favorite Annette F sold 2,524 shares
Sr. VP & Chief HR Officer @ $365.00 ($921.3K)
Sep 7, 2026 dark_pool
Jul 23, 2026 SEC Dark Pool: WST — 0.8M shares, 28,183 trades
Week starting 2026-09-07. Total ATS volume: 814,968 shares across 28,183 trades.
West Pharmaceutical Services reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted
8-K — Impact 7/10
West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating co
PRESS-RELEASE — Impact 7/10
This PRESS-RELEASE filing from West Pharmaceutical Services, Inc. (WST) announces the upcoming second-quarter 2026 earni
PRESS-RELEASE — Impact 1/10
Jun 30, 2026 Inst.
FMR LLC — DOUBLED
3,574,816 shares ($1.3B)
Analyst ratings buy % +18.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | Morgan Stanley | UPGRADE | Overweight | 55% |
| Sep 9, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 3, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 27, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Jul 13, 2026 | BNP Paribas | INITIATE | Outperform | — |
| Jul 9, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Jul 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Jul 2, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
| Jun 9, 2026 | Barclays | UPGRADE | Overweight | 54% |
| Jun 2, 2026 | Stephens & Co. | REITERATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 14 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 7 | 14 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 8 | 12 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 7 | 11 | 4 | 0 | 0 | 82% | |
| May 1, 2026 | 6 | 13 | 4 | 0 | 0 | 83% | |
| Apr 1, 2026 | 6 | 12 | 5 | 0 | 0 | 78% | |
| Mar 1, 2026 | 6 | 12 | 5 | 0 | 0 | 78% | |
| Feb 1, 2026 | 6 | 12 | 5 | 0 | 0 | 78% |
Price targets
Where 16 covering analysts think WST trades over the next 12 months.
$407.56 +11.7% upside Buy
Current$365.03 Low$340.00 Median$410.00 High$459.00 16 analysts
$340.00$459.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 3 bullish, 1 bearish, 0 mixed, 8 neutral · avg impact 3.7/10.
BULLISH8-K7/10
West Pharmaceutical Services reported Q2 2026 results that significantly exceeded consensus expectat
Jul 23, 2026
BULLISHPRESS-RELEASE7/10
West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18
Jul 23, 2026
NEUTRALPRESS-RELEASE1/10
This PRESS-RELEASE filing from West Pharmaceutical Services, Inc. (WST) announces the upcoming secon
Jul 7, 2026
BEARISH8-K7/10
West Pharmaceutical (WST) disclosed a material cybersecurity attack on May 7, 2026, with data exfilt
May 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 7, 2026
dark_pool
Dark Pool: WST — 0.8M shares, 28,183 trades
Week starting 2026-09-07. Total ATS volume: 814,968 shares across 28,183 trades.
Aug 31, 2026
dark_pool
Dark Pool: WST — 0.5M shares, 26,091 trades
Week starting 2026-08-31. Total ATS volume: 535,144 shares across 26,091 trades.
Aug 26, 2026
other
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug
Aug 24, 2026
dark_pool
Dark Pool: WST — 0.7M shares, 32,565 trades
Week starting 2026-08-24. Total ATS volume: 714,747 shares across 32,565 trades.
Aug 21, 2026
ftd
FTD: WST — 1,588 shares ($0.6M) failed to deliver
Settlement: 20260821, Price: $353.77, FTD Value: $561,786.76, WEST PHARMACEUTICAL SERV INC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.19 | $2.16–$2.23 | 11.9% | +0.1% | 9↑ 0↓ | $0.8B | 13 |
| Next Q | $2.27 | $2.19–$2.32 | 11.4% | +0.1% | 4↑ 3↓ | $0.8B | 12 |
| Current FY | $8.96 | $8.83–$9.05 | 22.9% | +0.0% | 14↑ 0↓ | $3.4B | 17 |
| Next FY | $9.98 | $9.71–$10.67 | 11.4% | +0.2% | 14↑ 0↓ | $3.6B | 17 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.193 | — |
| 7d ago | $2.193 | — |
| 30d ago | $2.190 | +0.003 |
| 60d ago | $2.190 | +0.003 |
| 90d ago | $2.125 | +0.067 |
Institutional ownership
Which big funds own WST (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $18.4B total value (51,207,537 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,651,784 | $2.4B | 13.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,613,134 | $1.7B | 9.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,015,766 | $1.4B | 7.9% | — |
| FMR LLC | 3,574,816 | $1.3B | 7.0% | DOUBLED +186.0% |
| STATE STREET CORP | 3,348,698 | $1.2B | 6.6% | — |
| Artisan Partners Limited Partnership | 2,411,792 | $865.8M | 4.7% | — |
| Bank of New York Mellon Corp | 2,043,823 | $733.7M | 4.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,903,279 | $680.6M | 3.7% | — |
| MORGAN STANLEY | 1,582,546 | $568.1M | 3.1% | — |
| JPMORGAN CHASE & CO | 1,164,527 | $413.0M | 2.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 1,249,748 | 3,574,816 | +186.0% | $1.3B |
| NORGES BANK | NEW | — | 862,915 | — | $309.8M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | TRIM | 705,336 | 507,786 | -28.0% | $182.3M |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | ADD | 388,239 | 495,334 | +27.6% | $177.8M |
| APG Asset Management N.V. | TRIM | 1,267,282 | 560,582 | -55.8% | $176.0M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | DOUBLED | 39,725 | 417,309 | +950.5% | $149.8M |
| Amundi | TRIM | 644,065 | 385,311 | -40.2% | $138.3M |
| UBS Group AG | ADD | 275,508 | 374,361 | +35.9% | $134.4M |
| Quantinno Capital Management LP | ADD | 161,478 | 308,116 | +90.8% | $110.6M |
| Point72 Asset Management, L.P. | ADD | 159,350 | 283,396 | +77.8% | $101.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$6.6M — $0.00 bought, $6.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | HAUGEN JANET BRUTSCHEA | Director | AWARD | 44 | $370.76 | $16.3K |
| Sep 15, 2026 | Favorite Annette F | Sr. VP & Chief HR Officer | EXERCISE | 2,524 | $89.64 | $226.3K |
| Sep 15, 2026 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2,524 | $365.00 | $921.3K |
| Sep 14, 2026 | Favorite Annette F | Sr. VP & Chief HR Officer | EXERCISE | 2,500 | $89.64 | $224.1K |
| Sep 14, 2026 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2,500 | $355.00 | $887.5K |
| Sep 11, 2026 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2,500 | $345.00 | $862.5K |
| Sep 11, 2026 | Favorite Annette F | Sr. VP & Chief HR Officer | EXERCISE | 2,500 | $89.64 | $224.1K |
| Sep 8, 2026 | Lagarde Michel | President and CEO | AWARD | 13,879 | — | — |
| Sep 8, 2026 | Lagarde Michel | President and CEO | AWARD | 11,081 | — | — |
| Sep 8, 2026 | Lagarde Michel | President and CEO | AWARD | 12,088 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for WST.
Shares short
2,378,099
Settlement Sep 15, 2026
Change vs prior
+8.3%
Semi-monthly cycle
Days to cover
4.5
At avg daily volume
Of shares outstanding
≈3.4%
Estimate — not % of float
All WST filing & press-release reports (12)
- 8-K reportJul 23, 2026
- PRESS-RELEASE reportJul 23, 2026
- PRESS-RELEASE reportJul 7, 2026
- 8-K reportMay 11, 2026
- CLUSTER reportMay 6, 2026
- CLUSTER reportMay 6, 2026
- CLUSTER reportMay 6, 2026
- CLUSTER reportMay 6, 2026
- CLUSTER reportMay 6, 2026
- CLUSTER reportApr 29, 2026
- 8-K reportApr 23, 2026
- DEFA14A reportMar 12, 2026